Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
KURA Quote, Financials, Valuation and Earnings
Last price:
$8.67
Seasonality move
:
-0.17%
Day range:
$8.85 - $9.47
52-week range:
$5.41 - $12.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.24x
P/B ratio:
4.39x
Volume:
1.3M
Avg. volume:
1.5M
1-year change:
25.78%
Market cap:
$764.1M
Revenue:
$67.5M
EPS (TTM):
-$3.18
Analysts' Opinion
-
Consensus RatingKura Oncology, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.27, Kura Oncology, Inc. has an estimated upside of 273.1% from its current price of $9.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -73.41% downside risk from its current price of $9.22.
Fair Value
-
According to the consensus of 12 analysts, Kura Oncology, Inc. has 273.1% upside to fair value with a price target of $32.27 per share.
KURA vs. S&P 500
-
Over the past 5 trading days, Kura Oncology, Inc. has underperformed the S&P 500 by -3.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kura Oncology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kura Oncology, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kura Oncology, Inc. reported revenues of $17.3M.
Earnings Growth
-
Kura Oncology, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Kura Oncology, Inc. reported earnings per share of -$0.92.
Enterprise value:
117.3M
EV / Invested capital:
0.60x
Price / LTM sales:
11.24x
EV / EBIT:
--
EV / Revenue:
1.74x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-1.66x
Price / Operating cash flow:
9.00x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$66.4M
Return On Assets:
-36.15%
Net Income Margin (TTM):
-412.95%
Return On Equity:
-92.88%
Return On Invested Capital:
-87.33%
Operating Margin:
-497.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $53.9M | $67.5M | $53.9M | $17.3M | |
| Gross Profit | -$849K | $53M | $66.4M | $53.7M | $16.9M | |
| Operating Income | -$165.8M | -$193.2M | -$303.6M | -$22.5M | -$86.3M | |
| EBITDA | -$165M | -$192.3M | -$302.6M | -$22.3M | -$85.9M | |
| Diluted EPS | -$2.08 | -$2.02 | -$3.18 | -$0.22 | -$0.92 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $522.3M | $446.4M | $432.5M | $744.8M | $708.7M | |
| Total Assets | $534.1M | $456.3M | $448.9M | $1B | $738.4M | |
| Current Liabilities | $22.5M | $24.1M | $35.3M | $78.7M | $117M | |
| Total Liabilities | $27.4M | $36M | $51.7M | $627M | $564.2M | |
| Total Equity | $506.6M | $420.3M | $397.3M | $413.6M | $174.1M | |
| Total Debt | $4.6M | $11.7M | $15.7M | $14.7M | $19.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$124.8M | $134.3M | -$64.1M | $269.1M | $117.3M | |
| Cash From Investing | $15.6M | -$101.6M | -$13.1M | -$95M | -$64.6M | |
| Cash From Financing | $94.8M | $154.4M | $1.8M | $806K | $1.1M | |
| Free Cash Flow | -$125M | $133.8M | -$70.7M | $268.8M | $115M | |
KURA
Sector
Market Cap
$764.1M
$25.1M
Price % of 52-Week High
69.26%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
-0.28%
-1.6%
1-Year Price Total Return
18.82%
-18.38%
Beta (5-Year)
0.224
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.88
200-day SMA
Buy
Level
$8.44
Bollinger Bands (100)
Sell
Level
8.52 - 10.92
Chaikin Money Flow
Buy
Level
2.6M
20-day SMA
Buy
Level
$8.60
Relative Strength Index (RSI14)
Buy
Level
61.33
ADX Line
Buy
Level
21.6
Williams %R
Neutral
Level
-52.7778
50-day SMA
Buy
Level
$8.77
MACD (12, 26)
Buy
Level
2.05
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
1.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.5595)
Sell
CA Score
(Annual)
Level (-2.7536)
Buy
Beneish M-Score
(Annual)
Level (-5.0333)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.6823)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, KURA has received 11 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KURA average analyst price target in the past 3 months is $32.27.
-
Where Will Kura Oncology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kura Oncology, Inc. share price will rise to $32.27 per share over the next 12 months.
-
What Do Analysts Say About Kura Oncology, Inc.?
Analysts are divided on their view about Kura Oncology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kura Oncology, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Kura Oncology, Inc.'s Price Target?
The price target for Kura Oncology, Inc. over the next 1-year time period is forecast to be $32.27 according to 12 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KURA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kura Oncology, Inc. is a Buy. 11 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KURA?
You can purchase shares of Kura Oncology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kura Oncology, Inc. shares.
-
What Is The Kura Oncology, Inc. Share Price Today?
Kura Oncology, Inc. was last trading at $8.67 per share. This represents the most recent stock quote for Kura Oncology, Inc.. Yesterday, Kura Oncology, Inc. closed at $9.22 per share.
-
How To Buy Kura Oncology, Inc. Stock Online?
In order to purchase Kura Oncology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KURA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KURA
Sector
P/E ratio
--
21.37x
PEG ratio
-0.05x
-0.01x
P/B ratio
4.39x
1.73x
Price / LTM sales
11.24x
1.46x
Growth Metrics
KURA
Sector
Revenue growth
-67.83%
3.27%
Earnings growth
-317.19%
12.13%
Revenue (5-year growth)
--
6.25%
Earnings forecast
-$0.49
-$0.20
Profitability
KURA
Sector
Profitability FY 2025
$66.4M
$2.3M
Return on invested capital
-87.33%
-33.43%
Return on assets
-36.15%
-29.94%
Return on equity
-92.88%
-40.07%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
May
7
Estimated Next Earnings Date
Jun
4
Balance Sheet
KURA
Sector
Total cash
$667.2M
$24.9M
Short term investments
$502.9M
$23M
Total assets
$738.4M
$70.1M
Long term debt
$19.2M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
